AOD-9604: A GH Fragment That Failed as a Drug and Was Rebranded as a Joint-Health Supplement

AOD-9604 is a synthetic fragment of human growth hormone—specifically amino acids 176–191 of the hGH molecule, with an added tyrosine residue—designed to isolate the fat-metabolizing activity of growth hormone without triggering its growth-promoting or diabetogenic effects. Developed by Metabolic Pharmaceuticals in Melbourne, it advanced further through clinical development than most peptides in this space. An earlier 12-week trial showed a modest positive signal—subjects receiving 1 mg/day lost approximately 1.8 kg more than placebo—which justified a larger Phase IIb trial enrolling roughly 300 obese patients over 24 weeks. That larger trial failed its primary endpoint. AOD-9604 did not produce statistically significant weight loss compared to placebo.

This article traces the full arc—from the genuine preclinical science that made AOD-9604 interesting, through the clinical trial that killed its drug development, to its second life as an Australian food-supplement ingredient and its current popularity in peptide-community protocols for fat loss and, increasingly, joint health. We examine every major claim against the actual published evidence, explain why the GRAS designation does not mean what vendors imply it means, and evaluate whether any use case survives honest scrutiny.

Quick Facts

What Is AOD-9604?

AOD-9604 is a synthetic peptide comprising 16 amino acids, derived from the C-terminal fragment of human growth hormone. Specifically, it corresponds to amino acids 176-191 of native hGH, with a single modification: a tyrosine residue inserted at position 177. This small edit was intentional—designed to enhance receptor binding and metabolic activity compared to the unmodified fragment.

The peptide was engineered on the hypothesis that the lipolytic (fat-mobilizing) properties of hGH could be separated from its growth-promoting and metabolic side effects. Full hGH stimulates growth, increases insulin resistance, and can precipitate diabetes in susceptible individuals. The reasoning: if the 176-191 fragment is responsible for fat mobilization, synthesizing it in isolation might deliver fat loss without these complications. This logic is scientifically sound in principle—different regions of hGH do bind different receptors and trigger different pathways. The practical evidence, however, undermines this promise.

Origins and Discovery

AOD-9604 was developed in the late 1990s by researchers at Monash University in Melbourne, Australia, led by Frank Ng and colleagues. The work emerged from a broader body of research on hGH fragment activity. At the time, the therapeutic potential of growth hormone was well recognized, but so were its adverse effects—hyperglycemia, insulin resistance, carpal tunnel syndrome, acromegaly-like changes with chronic use. The Monash team set out to isolate the metabolic benefits from the growth-promoting liabilities.

Metabolic Pharmaceuticals Ltd was founded to commercialize the discovery, and the compound entered clinical development under the generic name AOD-9604 (standing for Anti-Obesity Drug 9604). In the early 2000s, the company initiated human trials, advancing to Phase IIb by the mid-2000s. The clinical program, however, stalled after the Phase IIb failure. Metabolic Pharmaceuticals’ development pipeline contracted, and the company eventually pivoted toward other indications—notably, intra-articular injection of AOD-9604 for osteoarthritis, a much later and much smaller clinical program primarily conducted in Australia.

The mechanism research continued in academic settings, with in vitro and animal studies supporting the original hypothesis. However, these preclinical findings never translated to confirmed human efficacy. Despite the absence of positive human clinical evidence, AOD-9604 became available through research chemical suppliers, peptide vendors, and underground laboratories. Community adoption accelerated in the 2010s and 2020s, driven almost entirely by anecdotal reports and self-experimentation—a dissociation between evidence and use that is rare even in the wider peptide space.

Mechanism of Action

AOD-9604’s proposed mechanism centers on the beta-3 adrenergic receptor pathway. In cell culture and animal models, the peptide is reported to:

• Activate lipolysis: Increase the breakdown of stored triglycerides in adipose tissue, releasing free fatty acids for oxidation.
• Inhibit lipogenesis: Suppress the synthesis and storage of new fat, primarily through reduced acetyl-CoA carboxylase activity.
• Spare growth effects: Target the beta-3 adrenergic pathway without activating the IGF-1 axis or GH receptor pathways implicated in growth and metabolic complications.

The in vitro evidence supporting these mechanisms is moderately robust. Cell culture studies demonstrate that AOD-9604 increases lipolysis and reduces lipogenesis in isolated adipocytes, and rodent studies show modest reductions in body weight and fat mass. One frequently cited animal study reported that mice treated with AOD-9604 showed reduced weight gain and improved insulin sensitivity compared to controls. These findings fueled enthusiasm for human translation.

A key pharmacokinetic finding reinforces this gap: Moré and Kenley (2014) reported an approximate plasma half-life of three minutes following intravenous administration—rapid degradation that may partly explain the failure of oral formulations, which face both GI degradation and minimal systemic exposure even if absorbed.

Notably, Heffernan et al. (2001, PMID 11713213) demonstrated that beta-3 adrenergic receptor knockout mice were unresponsive to sustained lipolytic effects from AOD-9604. However, AOD-9604 did temporarily boost energy expenditure and fat oxidation even in the knockout animals—suggesting mechanisms beyond direct β3-AR activation may be involved. This nuance matters for the “It’s Complicated” tier assignment: the mechanism is real but incompletely understood.

However, a critical gap exists: the mechanisms confirmed in cell culture and rodent models have not been validated in humans. The human Phase IIb trial did not measure pathway-specific endpoints (e.g., adipose lipolytic markers, beta-3 receptor activation). It measured the clinical outcome—weight loss. That outcome was negative. Whether the proposed mechanism is intact in humans but simply insufficient to produce clinically meaningful fat loss, or whether the mechanism itself fails to engage in human physiology, remains unknown. The failure does not definitively rule out the mechanism, but it does mean the mechanism has no confirmed functional significance in humans.

Key Research Areas

Adipose Tissue Metabolism

The most extensive body of research examines AOD-9604’s effects on adipose tissue. In vitro studies using human and murine adipocytes show increased glycerol release (a marker of lipolysis) and reduced triglyceride content. Rodent models, particularly diet-induced obesity models, report modest reductions in total body weight and fat mass percentage, sometimes accompanied by improvements in glucose tolerance. However, the effect sizes in animals are small—typically 10–20% reductions in weight gain relative to control—and animal obesity models often respond to interventions that fail in humans.

Growth Hormone Receptor Independence

One proposed advantage of AOD-9604 is that it acts independently of the classical growth hormone receptor, thus avoiding the anabolic and metabolic complications of full hGH. Some in vitro studies suggest AOD-9604 does not activate canonical GH receptor signaling, supporting this claim. However, this has not been rigorously tested in humans. The Phase IIb trial did not measure IGF-1 levels or monitor for growth effects, so the independence from growth hormone receptor signaling in humans remains largely theoretical.

Pharmacokinetics and Formulation

A major variable is formulation and route of administration. The failed Phase IIb trial used oral administration. Peptides are typically broken down in the gastrointestinal tract, and oral bioavailability of AOD-9604 is likely to be minimal without additional modifications (permeation enhancers, enteric coating, etc.). The community predominantly uses subcutaneous injection, bypassing first-pass metabolism. This distinction is critical: the failed trial tested oral AOD-9604; the community uses injectable AOD-9604. Whether the latter would perform differently is unknown because it has never been tested in a controlled trial.

A 2014 comprehensive safety and metabolism review (Moré and Kenley, Journal of Endocrinology and Metabolism) synthesized nonclinical and clinical safety data from all six human trials involving approximately 900 participants. Ames testing showed no mutagenic potential. Chromosome aberration assays detected no clastogenic activity. Chronic rat studies (six months) and primate studies (nine months) demonstrated safety at high dosages. No participants in any trial developed detectable anti-AOD9604 antibodies, even after 24 weeks of continuous exposure. Plasma half-life was approximately three minutes following intravenous administration. This safety profile—which is genuinely clean—is the strongest element of AOD-9604’s evidence base, even as its efficacy data remains negative.

Osteoarthritis (Later Indication)

In the 2010s, AOD-9604 was repositioned for intra-articular injection in osteoarthritis. The most cited published study is Kwon and Park (2015, PMID 26275694), which tested intra-articular AOD-9604 injections in a rabbit osteoarthritis model: 32 rabbits with collagenase-induced knee OA received either AOD-9604 alone, hyaluronic acid (HA) alone, combined AOD-9604 + HA, or control injections. The combined group showed shorter lameness periods, lower cartilage degeneration scores, and better cartilage regeneration than either treatment alone. This is the only published OA study for AOD-9604, and it is in rabbits—not humans. A small number of clinical studies (primarily from Australia) have examined the human OA indication with some reporting improvements in joint pain and function, but this work has not led to drug approval in major markets.

Common Claims versus Current Evidence

AOD-9604 generates more community enthusiasm than its evidence warrants. The table below evaluates 12 widespread claims against what the published science actually shows.

Claim	What the Evidence Shows	Verdict
Reduces body weight	Phase IIb trial (n=300, 24 weeks, oral) failed primary endpoint; no statistically significant weight loss vs placebo.	Failed in Clinical Trial
Activates lipolysis in humans	Supported by in vitro and rodent data, but never directly measured in human trials.	Animal Studies Only — No Human Trials
Works when injected subcutaneously	No controlled human trials of subcutaneous injection; only community anecdotes. The failed trial used oral dosing.	No Evidence
Avoids growth-promoting effects of hGH	Theoretically sound, but not rigorously tested in human trials. IGF-1 was not monitored in the Phase IIb trial.	Plausible — Not Confirmed in Humans
Safe for long-term use	Phase IIb trial was 24 weeks; no long-term safety data in humans. No systematic toxicology.	Not Enough Data to Judge Safety
Superior to diet and exercise	The single controlled trial did not beat placebo for weight loss. By definition, it was not superior to any comparator.	Failed in Clinical Trial
Effective for osteoarthritis (intra-articular)	Small clinical studies from one region; some positive signals but not approved in major jurisdictions.	Limited Human Data — Small, Regional Studies
GRAS status means it is FDA-approved	GRAS applies only to oral food-ingredient use. It is not drug approval and does not authorize therapeutic claims of any kind.	Misleading — Widely Misrepresented
Improves insulin sensitivity	Some rodent data suggest improved glucose tolerance; never confirmed in human trials.	Animal Studies Only — No Human Trials
No side effects because it is a natural GH fragment	AOD-9604 is synthetic, not endogenous. Absence of reported adverse events in uncontrolled use is not safety data.	Misleading — Synthetic Compound
Better absorbed via injection than oral	Pharmacologically reasonable—peptides typically have poor oral bioavailability—but no controlled trial has compared routes.	Plausible — Not Confirmed in Humans
Stacks well with other peptides (CJC-1295, Ipamorelin)	Zero published studies testing any combination protocol. Entirely anecdotal from self-experimentation communities.	No Evidence

The pattern is clear: AOD-9604 is the rare peptide that actually reached a controlled clinical trial—and failed. Most compounds in this space never get tested in humans; AOD-9604 was tested and did not work. Community claims about subcutaneous injection, stacking protocols, and metabolic benefits rest on zero published human data. The only positive signals come from small regional osteoarthritis trials that have not led to regulatory approval.

We currently don’t have any vetted partners for this compound. Check back soon.

Human Evidence Landscape

The Earlier Positive Signal: 12-Week Trial

Before the Phase IIb, a smaller 12-week randomized trial tested oral AOD-9604 at 1 mg/day. Subjects receiving AOD-9604 lost an average of 2.6 kg compared to 0.8 kg in the placebo group—a net difference of approximately 1.8 kg. This modest but statistically significant result justified advancing to the larger Phase IIb trial. The subsequent 24-week trial with roughly 300 patients, however, failed to confirm this signal. The earlier positive result is worth noting for completeness—it explains why the compound advanced—but the larger, longer trial is the more definitive data point.

The Phase IIb Metabolic Pharmaceuticals Trial (The Definitive Data)

The cornerstone—and essentially the only—controlled human evidence for AOD-9604 as a weight-loss agent is the Phase IIb trial conducted by Metabolic Pharmaceuticals, completed circa 2007. The trial enrolled approximately 300 patients with obesity or overweight status, randomized to receive either AOD-9604 (oral formulation) or placebo over 24 weeks. The primary endpoint was weight loss.

Result: AOD-9604 did not produce statistically significant weight loss compared to placebo. The trial failed its primary endpoint. Secondary endpoints were not prominently reported in the published literature, suggesting they were equally disappointing or were not formally analyzed. The company’s development program contracted following this failure, and the compound was not advanced to Phase III.

This is not a marginal or equivocal finding. A Phase IIb trial is designed to gather preliminary efficacy and safety data to inform Phase III planning. When a Phase IIb trial fails its primary endpoint, it is standard practice to either redesign the approach (e.g., different dose, population, or formulation) or abandon the program. Metabolic Pharmaceuticals chose the latter course for weight loss, redirecting resources toward osteoarthritis.

Case Reports and Anecdotal Evidence

Numerous case reports and personal narratives describe weight loss, improved body composition, and reduced appetite in individuals self-administering AOD-9604 via subcutaneous injection. These anecdotes are published on forums, blogs, and social media, and are frequently cited to justify continued community use. However, anecdotal evidence is susceptible to multiple biases: placebo effect, concurrent dietary restriction, selection bias (only successful cases are reported), and recall bias.

In controlled research, anecdotal evidence is considered the lowest tier of evidence—below case series, observational studies, and clinical trials. The absence of a control group, blinding, and standardized outcome measurement makes it impossible to distinguish the effect of AOD-9604 from the effects of behavior change, expectation, and natural weight fluctuation.

Pharmacokinetic and Mechanistic Studies

A small number of human pharmacokinetic studies have been conducted, primarily examining oral formulations. These studies typically measure blood levels of AOD-9604 after administration but do not assess metabolic endpoints. Published results suggest that oral bioavailability is low—consistent with the expectation that peptides are degraded in the GI tract. The implications are significant: if oral AOD-9604 does not achieve measurable systemic levels, it is implausible that it would produce systemic metabolic effects.

The SC Injection Conundrum

Community advocates frequently argue that the Phase IIb trial failed because it used oral administration—a route unsuitable for peptides. They propose that subcutaneous injection, bypassing first-pass degradation, would be more effective. This is a reasonable hypothesis. However, it remains a hypothesis. No double-blind, placebo-controlled trial of SC AOD-9604 has been published. The supposed superiority of SC injection is inference, not evidence.

Safety, Risks, and Limitations

Adverse Events in the Phase IIb Trial

The Metabolic Pharmaceuticals Phase IIb trial reported on safety outcomes, though detailed safety data are not extensively published in open literature. General descriptions indicate that AOD-9604 was well-tolerated in the trial, with no serious adverse events reported. However, the trial spanned only 24 weeks, and safety monitoring for peptides typically requires longer-term follow-up, particularly if the compound were to be used chronically.

A 2014 comprehensive safety review (Moré and Kenley, Journal of Endocrinology and Metabolism) synthesized nonclinical and clinical safety data from all six human trials. Ames testing showed no mutagenic potential. Chromosome aberration assays detected no clastogenic activity. Chronic rat studies (six months) and primate studies (nine months) demonstrated safety at high dosages. No participants in any trial developed detectable anti-AOD9604 antibodies, even after 24 weeks of continuous exposure. This safety profile—which is genuinely clean—is the strongest element of AOD-9604’s evidence base.

Injection-Related Risks (SC Administration)

Community use of AOD-9604 is predominantly via subcutaneous injection. Risks associated with any SC peptide injection include:

• Infection: Improper injection technique, non-sterile reconstitution, or contaminated supply can lead to local or systemic infection.
• Lipohypertrophy: Repeated injection in the same site can cause localized fat accumulation or skin changes.
• Immune response: Peptides can trigger antibody formation, potentially reducing efficacy or triggering hypersensitivity reactions.
• Product quality: Community-sourced AOD-9604 often lacks third-party testing and may be impure, misdosed, or counterfeit.

Metabolic and Endocrine Risks

Although AOD-9604 is proposed to act independently of growth hormone receptors, this has not been exhaustively tested. Theoretical risks include:

• Hypoglycemia: Enhanced lipolysis and substrate mobilization could precipitate hypoglycemia, particularly in individuals with reduced carbohydrate intake.
• Appetite suppression: Community reports often mention reduced appetite; unintended appetite loss could lead to malnutrition or disordered eating patterns.
• Long-term endocrine effects: Unknown. Chronic activation of beta-3 adrenergic pathways in adipose tissue has not been long-term studied in humans receiving AOD-9604.

Quality Control and Sourcing Concerns

AOD-9604 is not approved as a pharmaceutical in the United States or most major markets. Community supplies derive from research chemical vendors, Chinese or Indian synthesis facilities, and underground laboratories. These sources typically do not employ pharmaceutical-grade quality control, sterility assurance, or stability testing. Purity, potency, and sterility of community-sourced AOD-9604 are uncertain.

Unknowns and Data Gaps

• No long-term safety data in humans (longest trial was 24 weeks)
• No data on subcutaneous injection safety or efficacy in controlled settings
• No data on interactions with medications
• No formal assessment of immunogenicity
• No data on pregnancy/lactation safety

Legal and Regulatory Status

FDA Status

AOD-9604 is not approved by the U.S. Food and Drug Administration as a drug. It failed to advance beyond Phase IIb development, and no new drug application (NDA) or abbreviated NDA was ever submitted. Metabolic Pharmaceuticals obtained Generally Recognized as Safe (GRAS) status for oral AOD-9604 for use as a food ingredient—a designation that applies to non-drug uses, such as food additive or dietary supplement ingredient. GRAS status is not drug approval; it is a regulatory pathway for food additives. This distinction is frequently misrepresented in marketing materials.

Under FDA regulations, AOD-9604 cannot be legally marketed or sold for weight loss or any therapeutic claim in the United States. It may, in theory, be sold as a research chemical or dietary supplement, but marketing claims related to weight loss, fat metabolism, or any disease state would violate FDA regulations and make the product an unapproved drug.

FDA Compounding Review (2024–2025)

In December 2024, AOD-9604 was presented to the FDA’s Pharmacy Compounding Advisory Committee (PCAC) for consideration as a bulk drug substance eligible for compounding under Section 503A of the FD&C Act. A presentation titled “Saving AOD9604” was submitted by Edwin Lee, MD. This review process is ongoing. Separately, in January 2025 the FDA published an interim policy that ended the Category 1/2/3 classification system for newly nominated bulk drug substances. Under the new framework, pharmacies may not compound with newly proposed substances until the FDA completes its review and formally includes the substance on the final 503A list. The practical implication: AOD-9604’s availability through US compounding pharmacies is in regulatory flux.

WADA Status

AOD-9604 is not explicitly listed on the WADA Prohibited List. However, peptide hormones and their analogues fall under the S2 category (Peptide Hormones, Growth Factors, Related Substances and Mimetics). Depending on jurisdictional interpretation, AOD-9604 could be considered a hGH analogue and thus prohibited. Athletes should verify with their sport’s governing body before use.

International Regulatory Landscape

Most major regulatory agencies—Health Canada, EMA, TGA (Australia), PMDA (Japan)—have not approved AOD-9604 as a therapeutic drug. Limited development continues for intra-articular osteoarthritis indication in some jurisdictions, but approval is not widely established. In many countries, possession of AOD-9604 without a prescription is illegal.

Research Chemical and Dietary Supplement Designation

AOD-9604 is sold in many jurisdictions under the “research chemical” or “not for human consumption” label, which is a regulatory loophole that allows sale despite lack of drug approval. This classification provides no assurance of quality, purity, potency, or safety. Buyers are assuming all risk.

Research Protocols

Theoretical Clinical Trial Design for AOD-9604 (Subcutaneous, Weight Loss)

If a rigorous clinical trial of subcutaneous AOD-9604 were designed today, a reasonable Phase IIb protocol would include:

• Population: Adults aged 18–65 with BMI 27–40, no uncontrolled diabetes, no active cardiovascular disease.
• Study duration: 12–24 weeks to assess short-term efficacy; longer follow-up to assess sustainability.
• Intervention: Subcutaneous AOD-9604 at doses informed by preliminary pharmacokinetic data (likely 100–500 mcg daily or divided), vs placebo.
• Primary endpoint: Change in body weight from baseline; secondary endpoints: body composition (DEXA or bioimpedance), lipid panel, fasting glucose, insulin, IGF-1.
• Safety monitoring: Injection-site reactions, vital signs, glucose monitoring, antibody titers against AOD-9604.
• Randomization and blinding: Double-blind, parallel-group design with concealed allocation.
• Sample size: n=150–200 per group, powered to detect 4–5 kg difference in weight loss.

Such a trial would definitively answer whether subcutaneous AOD-9604 produces weight loss superior to placebo. It has not been conducted. The gap between what should be done and what has been done is the essential problem in AOD-9604’s evidence base.

Dosing in Published Research

AOD-9604 has been studied across several formats—oral formulation in the Phase IIb trial, intraperitoneal and subcutaneous injection in rodent models, and intra-articular injection in small osteoarthritis trials. The table below summarizes all published dosing data. Note that the Phase IIb trial is the only large, controlled human study, and its exact dose was never widely published. All other human data are sparse or preliminary.

Study	Formulation	Route	Dose	Duration	Outcome
Earlier RCT (~12 weeks, oral)	Oral	By mouth	1 mg/day	12 weeks	Net 1.8 kg weight loss vs placebo (statistically significant); positive signal that justified Phase IIb
Metabolic Pharmaceuticals Phase IIb (2007)	Oral	By mouth	Dose not widely published (estimated 10–50 mg daily)	24 weeks	Failed primary endpoint — no significant weight loss vs placebo
Rodent studies (various)	Injectable	IP or SC	0.1–1 mg/kg	2–12 weeks	Modest reduction in weight gain and fat mass
In vitro adipocyte studies	N/A	Direct cell exposure	nM–µM concentrations	Hours to days	Increased lipolysis and reduced lipogenesis markers
Pharmacokinetic studies (oral, small n)	Oral	By mouth	Dose variable (e.g., 250 µg–5 mg)	Single dose or short-term	Low/minimal systemic bioavailability; high variability
Osteoarthritis (intra-articular, regional trials)	Injectable	Intra-articular	0.5–2 mg per injection	Single dose to repeated weekly	Early-stage data suggest possible benefit in joint pain; not approved major markets

Note: The Phase IIb trial is the only large, controlled human study. All other human data are sparse. Rodent data cannot be directly extrapolated to humans. The wide range of doses in community use (see next section) far exceeds what was tested in the single positive animal and in vitro studies.

Dosing in Self-Experimentation

Community use of AOD-9604 overwhelmingly favors subcutaneous injection—a route that was never tested in the controlled clinical trial. The doses below are derived entirely from self-experimentation forums and anecdotal reports. They have no published pharmacokinetic or efficacy basis. Our position: reporting what people actually do is not the same as endorsing it.

Route	Typical Dose Range (Community)	Frequency	Duration	Basis for Dosing
Subcutaneous injection	100–500 mcg (0.1–0.5 mg)	Daily or 5–6 days/week	8–24 weeks, often longer with breaks	Empirical; derived from underground forums and self-report. Not based on pharmacokinetic or efficacy data.
Oral (rare in community use)	10–100 mg	Daily	Variable	Minimal; oral bioavailability is presumed too low for efficacy, so this route is rarely used.
Intra-articular (rare)	0.5–2 mg per injection	Weekly to monthly	Variable	Based on limited clinical trials for osteoarthritis; almost no community use.

Important: Community dosing is not evidence-based. No controlled trial has tested the doses used in self-experimentation. Higher doses do not necessarily produce better results—the Phase IIb trial showed that even optimized oral dosing failed. Subcutaneous doses in community use have never been tested in a controlled setting.

Frequently Asked Questions

Related Peptides

AOD-9604 sits within Cluster A (Weight Loss & Metabolic) on Peptidings, alongside compounds like BPC-157, TB-500, and GHK-Cu. While AOD-9604 was originally developed for weight loss, its repositioning toward joint health and its GH-fragment mechanism place it in conversation with tissue-repair peptides. The comparison table below shows all Cluster A compounds side by side. Below that, we discuss the weight-loss comparators that readers most often ask about.

Weight-Loss Comparators

Readers researching AOD-9604 for fat loss inevitably encounter approved weight-loss agents. The contrast is stark: semaglutide (Wegovy) and tirzepatide (Zepbound) have robust Phase III evidence showing 10–22% body weight reduction over 68–72 weeks. Both are FDA-approved. AOD-9604 failed its only controlled trial. GH secretagogues (sermorelin, ipamorelin, CJC-1295) raise endogenous GH and have some body-composition data, but none are approved for weight loss and all carry GH-related risks (hyperglycemia, carpal tunnel). AOD-9604 is the least proven option in this category by a wide margin.

Summary

AOD-9604 represents a compelling scientific hypothesis that failed to translate into human efficacy. The idea — isolate the fat-burning fragment of human growth hormone while leaving growth-promoting and diabetogenic effects behind — is elegant, and the in vitro and rodent data supporting the mechanism are reasonable. But the only double-blind, placebo-controlled clinical trial in humans, a Phase IIb study of approximately 300 patients over 24 weeks, found that oral AOD-9604 did not produce statistically significant weight loss compared to placebo.

This negative result should be the anchor point for any scientific discussion of AOD-9604. It is not the absence of evidence; it is evidence of absence. Yet community adoption has accelerated despite this. The disconnect is driven by anecdotal reports of weight loss from subcutaneous self-injection (a route never tested in controlled trials), misrepresentation of GRAS food-ingredient status as drug approval, and the general appeal of a “secret” fat-loss compound not available by prescription. These factors fuel demand, but they do not change the science.

Verdict Recapitulation

Evidence Tier: ~IT’S COMPLICATED

Verdict: Eyes Open

AOD-9604 earns “Eyes Open” and “It’s Complicated” because the evidence picture is genuinely nuanced. Six human trials with approximately 900 participants produced clean safety data but negative efficacy data. A Phase IIb trial of approximately 300 obese patients found no statistically significant weight loss from oral AOD-9604 versus placebo over 24 weeks. That is a failed clinical trial, not a gap in the literature. The compound was subsequently repositioned for osteoarthritis with almost no published evidence supporting that pivot. Calling this “preclinical only” would erase the substantial human data that exists—it simply happens to be negative for efficacy.

It does not earn “Reasonable Bet” because negative clinical data is more informative than positive animal data. The in vitro lipolysis assays and obese rodent studies demonstrate a real mechanism — beta-3 adrenergic receptor-independent fat oxidation — but mechanisms do not guarantee clinical efficacy. The hypothetical argument that subcutaneous AOD-9604 would succeed where oral failed is reasonable and testable, but it has not been tested. Until a properly designed clinical trial of SC AOD-9604 is conducted and published, the default position must reflect the evidence we actually have.

For readers considering AOD-9604: the honest assessment is that this compound had a legitimate scientific rationale and advanced further into clinical development than most peptides in this cluster — and it still failed. The only controlled trial found no effect versus placebo. All positive reports are anecdotal and uncontrolled. Quality of community-sourced AOD-9604 is uncertain. Approved weight-loss agents (semaglutide, tirzepatide) have far superior evidence. Proceed knowing exactly what the science says and what it does not.

References

1. Ng, F. M., et al. “Effect of an antilipogenic fragment of human growth hormone on glucose transport in rat adipocytes.” International Journal of Obesity, 1994. PubMed
2. Ng, F. M., et al. “Effects of oral administration of a synthetic fragment of human growth hormone on lipid metabolism.” Obesity Research, 2000. PubMed
3. Ng, F. M., et al. “Molecular and cellular actions of a structural domain of human growth hormone (AOD9401) on lipid metabolism in Zucker fatty rats.” Journal of Molecular Endocrinology, 2000. PubMed
4. Ng, F. M., et al. “Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone.” Hormone Research, 2000. PubMed
5. Heffernan, M., et al. “Increase of fat oxidation and weight loss in obese mice caused by chronic treatment with human growth hormone or a modified C-terminal fragment.” International Journal of Obesity, 2001. PubMed
6. Heffernan, M., et al. “The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knock-out mice.” Endocrinology, 2001. PubMed
7. Wilding, J. “AOD-9604 Metabolic Pharmaceuticals.” Current Opinion in Investigational Drugs, 2004. PubMed
8. Metabolic Pharmaceuticals Ltd. Phase IIb clinical trial of AOD-9604 for obesity. Completed circa 2007. Oral administration, 24 weeks, approximately 300 patients. Failed primary endpoint (weight loss vs. placebo). Full results remain in proprietary format; no peer-reviewed publication of primary outcome data.
9. Thomas, A., et al. “Detection and in vitro metabolism of AOD9604.” Rapid Communications in Mass Spectrometry, 2014. PubMed
10. Moré, M.I., Kenley, D. “Safety and Metabolism of AOD9604, a Novel Nutraceutical Ingredient for Improved Metabolic Health.” Journal of Endocrinology and Metabolism, 2014;4(3). DOI: 10.14740/jem213w. Comprehensive safety review covering all six human trials (~900 patients), nonclinical toxicology, pharmacokinetics (~3 min IV half-life).
11. Kwon, D.R., Park, G.Y. “Effect of Intra-articular Injection of AOD9604 with or without Hyaluronic Acid in Rabbit Osteoarthritis Model.” Annals of Clinical and Laboratory Science, 2015;45(4):426–32. PubMed
12. U.S. Food and Drug Administration. GRAS Notification for AOD-9604 as a food ingredient. GRAS status applies to oral food-ingredient use only—it is not drug approval and does not authorize therapeutic claims.
13. World Anti-Doping Agency (WADA). Prohibited List, 2025–2026. Peptide hormones and analogues fall under category S2; AOD-9604 is not explicitly listed but may be covered as an hGH fragment analogue.

Further Reading

On Peptidings:

• 5-Amino-1MQ: What the Research Actually Shows — NNMT inhibitor comparison for metabolic targets
• Cagrisema: What the Research Actually Shows — next-generation weight-loss peptide in clinical trials
• BPC-157: What the Research Actually Shows — tissue-repair peptide with the deepest preclinical portfolio
• Peptidings Guide: Understanding Evidence Levels — how we assign evidence tiers and verdicts
• Peptidings Guide: How to Read a Study — evaluate clinical evidence for yourself

External Resources:

• PubMed: AOD-9604 search results — all indexed research on AOD-9604
• FDA GRAS Notice Inventory — verify what GRAS status actually means
• WADA Prohibited List — peptide hormones and analogues (category S2)
• FDA Guidance: Developing Products for Weight Management — regulatory framework for obesity drug development
• ClinicalTrials.gov: AOD-9604 — registered clinical trials